Clinical Trial Update: Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

This document reports the results of a Phase 2 clinical trial evaluating efavirenz as second-line therapy for metastatic pancreatic cancer. The study has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• EFAVIRENZ (efavirenz)

Snippet

Sponsor: Institut Bergonié | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-08-28